{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:36:25Z","timestamp":1791426985015,"version":"4.3.3"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Rubella virus is the most teratogenic virus known to science and is capable of causing large epidemics. The RA 27\/3 rubella vaccine, usually combined with measles vaccine, has eliminated rubella and congenital rubella syndrome from much of the world, notably from the Western Hemisphere. Except in immunosuppressed individuals, it is remarkably safe. Together with rubella vaccine strains used in China and Japan, eradication of the rubella virus is possible, indeed more feasible than eradication of measles or mumps.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa530","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T19:14:08Z","timestamp":1597691648000},"page":"S360-S366","source":"Crossref","is-referenced-by-count":38,"title":["Rubella Eradication: Not Yet Accomplished, but Entirely Feasible"],"prefix":"10.1093","volume":"224","author":[{"given":"Stanley A","family":"Plotkin","sequence":"first","affiliation":[{"name":"Emeritus Professor of Pediatrics, University of Pennsylvania, Vaxconsult, Doylestown, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"2021093007540336500_CIT0001","first-page":"1","article-title":"Recommendations of the International Task Force for Disease Eradication","volume":"42(RR-16)","year":"1993","journal-title":"MMWR Recomm Rep"},{"key":"2021093007540336500_CIT0002","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.15585\/mmwr.mm6848a1","article-title":"Progress toward regional measles elimination\u2014worldwide, 2000\u20132018","volume":"68","author":"Patel","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021093007540336500_CIT0003","doi-asserted-by":"crossref","first-page":"855","DOI":"10.15585\/mmwr.mm6839a5","article-title":"Progress toward rubella and congenital rubella syndrome control and elimination\u2014worldwide, 2000\u20132018","volume":"68","author":"Grant","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021093007540336500_CIT0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jpids\/piy038","article-title":"Mumps: a pain in the neck","volume":"7","author":"Plotkin","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021093007540336500_CIT0005","first-page":"61","article-title":"Report of the thirtieth meeting of the International Task Force for disease eradication, 22 October 2019","volume":"95","author":"World Health Organization","year":"2020","journal-title":"Wkly Epidemiol Rec"},{"key":"2021093007540336500_CIT0006","article-title":"Chapter 53: Rubella vaccines.","volume-title":"Plotkin\u2019s vaccines","author":"Reef","year":"2017","edition":"7th ed."},{"key":"2021093007540336500_CIT0007","first-page":"301","article-title":"Rubella vaccines: WHO position paper","volume":"86","author":"World Health Organization","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"2021093007540336500_CIT0008","first-page":"301","article-title":"Rubella vaccines: WHO position paper","volume":"95","author":"World Health Organization","year":"2020","journal-title":"Wkly Epidemiol Rec"},{"key":"2021093007540336500_CIT0009","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1086\/368034","article-title":"New horizons in the control of rubella and prevention of congenital rubella syndrome in the Americas","volume":"187","author":"Castillo-Sol\u00f3rzano","year":"2003","journal-title":"J Infect Dis"},{"key":"2021093007540336500_CIT0010","doi-asserted-by":"crossref","first-page":"S571","DOI":"10.1093\/infdis\/jir472","article-title":"Elimination of rubella and congenital rubella syndrome in the Americas","volume":"204","author":"Castillo-Sol\u00f3rzano","year":"2011","journal-title":"J Infect Dis"},{"key":"2021093007540336500_CIT0011","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1093\/infdis\/jir104","article-title":"Status of rubella and congenital rubella syndrome surveillance, 2005\u20132009, the World Health Organization European Region","volume":"204","author":"Zimmerman","year":"2011","journal-title":"J Infect Dis"},{"key":"2021093007540336500_CIT0012","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1016\/j.vaccine.2017.06.042","article-title":"Progress and challenges in measles and rubella elimination in the WHO European Region","volume":"36","author":"Datta","year":"2018","journal-title":"Vaccine"},{"key":"2021093007540336500_CIT0013","doi-asserted-by":"crossref","first-page":"744","DOI":"10.15585\/mmwr.mm6924a4","article-title":"Progress toward rubella elimination\u2014Western Pacific Region, 2000\u20132019","volume":"69","author":"Knapp","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021093007540336500_CIT0014","doi-asserted-by":"crossref","first-page":"108","DOI":"10.29245\/2578-3009\/2018\/si.1116","article-title":"The impact of recent rubella vaccine introduction in 5 countries in the African Region","author":"Luce","year":"2018","journal-title":"J Immunol Sci"},{"key":"2021093007540336500_CIT0015","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/risa.12459","article-title":"The costs and valuation of health impacts of measles and rubella risk management policies","volume":"36","author":"Thompson","year":"2016","journal-title":"Risk Anal"},{"key":"2021093007540336500_CIT0016","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/21645515.2018.1532257","article-title":"The impact of measles-rubella vaccination on the morbidity and mortality from congenital rubella syndrome in 92 countries","volume":"15","author":"Vynnycky","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2021093007540336500_CIT0017","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/infdis\/jir100","article-title":"Proceedings of the Global Technical Consultation to assess the feasibility of measles eradication, 28\u201330 July 2010","volume":"204","author":"World Health Organization","year":"2011","journal-title":"J Infect Dis"},{"key":"2021093007540336500_CIT0018","first-page":"1","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, Nov. 2010. Summary, conclusions and recommendations","volume":"86","author":"World Health Organization","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"2021093007540336500_CIT0019","first-page":"61","article-title":"Meeting of the International Task for Disease Eradication, Nov. 2015","volume":"91","author":"World Health Organization","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"2021093007540336500_CIT0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/jpids\/piz043","article-title":"Measles: breakouts and breakthroughs","volume":"8","author":"Plotkin","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021093007540336500_CIT0021","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1016\/j.vaccine.2016.06.002","article-title":"A 16-year review of seroprevalence studies on measles and rubella","volume":"34","author":"Dimech","year":"2016","journal-title":"Vaccine"},{"key":"2021093007540336500_CIT0022","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1086\/605410","article-title":"Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine","volume":"200","author":"LeBaron","year":"2009","journal-title":"J Infect Dis"},{"key":"2021093007540336500_CIT0023","doi-asserted-by":"crossref","first-page":"A35","DOI":"10.1016\/j.vaccine.2017.10.065","article-title":"Measles and Rubella Global Strategic Plan 2012\u20132020 midterm review report: background and summary","volume":"36","author":"Orenstein","year":"2018","journal-title":"Vaccine"},{"key":"2021093007540336500_CIT0024","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1016\/j.vaccine.2018.10.007","article-title":"Global landscape of measles and rubella surveillance","volume":"36","author":"Patel","year":"2018","journal-title":"Vaccine"},{"key":"2021093007540336500_CIT0025","article-title":"Rubella infection in pregnancy and congenital rubella in United Kingdom, 2003 to 2016","volume":"23:17-00381","author":"Bukasa","year":"2018","journal-title":"Euro Surveill"},{"key":"2021093007540336500_CIT0026","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.vaccine.2018.11.017","article-title":"Last cases of rubella and congenital rubella syndrome in Spain, 1997-2016: the success of a vaccination program","volume":"37","author":"Sepp\u00e4l\u00e4","year":"2019","journal-title":"Vaccine"},{"key":"2021093007540336500_CIT0027","article-title":"Resurgence risk for measles, mumps and rubella in France in 2018 and 2020","volume":"23:1700796","author":"Beraud","year":"2018","journal-title":"Euro Surveill"},{"key":"2021093007540336500_CIT0028","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1186\/s12889-019-7829-3","article-title":"Immunity to rubella: an Italian retrospective cohort study","volume":"19","author":"Bianchi","year":"2019","journal-title":"BMC Public Health"},{"key":"2021093007540336500_CIT0029","article-title":"Congenital rubella still a public health problem in Italy: analysis of national surveillance data from 2005 to 2013","volume":"20:21103","author":"Giambi","year":"2015","journal-title":"Euro Surveill"},{"key":"2021093007540336500_CIT0030","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.15585\/mmwr.mm6736a4","article-title":"Sentinel surveillance for congenital rubella syndrome\u2014India, 2016-2017","volume":"67","author":"Murhekar","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021093007540336500_CIT0031","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/tropej\/fmy045","article-title":"Congenital rubella syndrome at tertiary care hospital in north India: results from a retrospective assessment","volume":"65","author":"Pilania","year":"2019","journal-title":"J Trop Pediatr"},{"key":"2021093007540336500_CIT0032","doi-asserted-by":"crossref","first-page":"17982","DOI":"10.1038\/s41598-017-18281-2","article-title":"Progress towards rubella elimination after implementation of rubella immunization for over 20 years in Shandong province, China","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"2021093007540336500_CIT0033","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12879-018-3032-x","article-title":"Rubella seroprevalence among pregnant women in Beijing, China","volume":"18","author":"Meng","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2021093007540336500_CIT0034","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.vaccine.2018.03.013","article-title":"Epidemiological profile and progress toward rubella elimination in China. 10 years after nationwide introduction of rubella vaccine","volume":"36","author":"Su","year":"2018","journal-title":"Vaccine"},{"key":"2021093007540336500_CIT0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2019.02.021","article-title":"Predicting congenital rubella syndrome in Japan, 2018-2019","volume":"82","author":"Lee","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2021093007540336500_CIT0036","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1473-3099(18)30356-6","article-title":"Towards rubella elimination in Japan","volume":"18","author":"Jindai","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021093007540336500_CIT0037","article-title":"Rubella resurgence in Japan 2018\u20132019","volume":"26:taz047","author":"Ujiie","year":"2019","journal-title":"J Travel Med"},{"key":"2021093007540336500_CIT0038","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.vaccine.2018.03.086","article-title":"Australian rubella serosurvey 2012-2013: on track for elimination?","volume":"36","author":"Edirisuriya","year":"2018","journal-title":"Vaccine"},{"key":"2021093007540336500_CIT0039","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5365\/wpsar.2015.6.4.005","article-title":"An outbreak investigation of congenital rubella syndrome in Solomon Islands, 2013","volume":"7","author":"Durski","year":"2016","journal-title":"Western Pac Surveill Response J"},{"key":"2021093007540336500_CIT0040","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/jmv.24517","article-title":"Genotypes of rubella virus and the epidemiology of rubella infections in the Democratic Republic of the Congo, 2004-2013","volume":"88","author":"Pukuta","year":"2016","journal-title":"J Med Virol"},{"key":"2021093007540336500_CIT0041","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/jmv.25252","article-title":"Epidemiology of rubella infection and genotyping of rubella virus in Cote d\u2019Ivoire, 2012-2016","volume":"90","author":"Kadjo","year":"2018","journal-title":"J Med Virol"},{"key":"2021093007540336500_CIT0042","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12879-019-3873-y","article-title":"Rubella outbreak in the school children, Addis Ababa, Ethiopia: February-April 2018","volume":"19","author":"Dinede","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2021093007540336500_CIT0043","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijid.2019.12.018","article-title":"Rubella seroprevalence in pregnant women living with and without HIV in Soweto, South Africa","volume":"91","author":"Gieles","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2021093007540336500_CIT0044","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13052-016-0264-5","article-title":"Serological evidence of acute rubella infection among under-fives in Mwanza: a threat to increasing rates of congenital rubella syndrome in Tanzania","volume":"42","author":"Mirambo","year":"2016","journal-title":"Ital J Pediatr"},{"key":"2021093007540336500_CIT0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/INF.0000000000001703","article-title":"Prevalence of rubella antibodies among children in the Democratic Republic of the Congo","volume":"37","author":"Alfonso","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2021093007540336500_CIT0046","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/cid\/ciy758","article-title":"Congenital rubella syndrome surveillance in South Africa using a sentinel site approach: a cross-sectional study","volume":"68","author":"Motaze","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021093007540336500_CIT0047","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.vaccine.2019.11.070","article-title":"Safety profile of rubella vaccine administered to pregnant women: a systematic review of pregnancy related adverse events following immunisation, including congenital rubella syndrome and congenital rubella infection in the foetus or infant","volume":"38","author":"Mangtani","year":"2020","journal-title":"Vaccine"},{"key":"2021093007540336500_CIT0048","doi-asserted-by":"crossref","first-page":"e1008080","DOI":"10.1371\/journal.ppat.1008080","article-title":"Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies","volume":"15","author":"Perelygina","year":"2019","journal-title":"PLoS Pathog"},{"key":"2021093007540336500_CIT0049","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1016\/j.vaccine.2019.07.049","article-title":"Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: a 10-year follow-up","volume":"37","author":"Carryn","year":"2019","journal-title":"Vaccine"},{"key":"2021093007540336500_CIT0050","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1377\/hlthaff.2015.1055","article-title":"Slow progress in finalizing measles and rubella elimination in the European Region","volume":"35","author":"Biellik","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"2021093007540336500_CIT0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vaccine.2017.11.062","article-title":"Measles and rubella eradication","volume":"36","author":"Hinman","year":"2018","journal-title":"Vaccine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_4\/S360\/40481482\/jiaa530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_4\/S360\/40481482\/jiaa530.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T07:55:56Z","timestamp":1632988556000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/Supplement_4\/S360\/6378085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":51,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2021,9,30]]},"published-print":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa530","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,9,30]]}}}